Target intelligence / Profile preview

Interleukin-23 p19 Subunit (IL-23p19)

Target
IL-23p19
Molecular classification
Cytokine, Interleukin, Four α-helical bundle cytokine
01

Overview

The Interleukin-23 p19 subunit (IL-23p19) is a key component of the IL-23 cytokine, which plays a crucial role in the maintenance and expansion of Th17 cells and the promotion of pro-inflammatory responses. IL-23p19 forms a heterodimer with the IL-12p40 subunit to create the biologically active IL-23 cytokine. By specifically targeting IL-23p19, therapeutic antibodies can selectively inhibit IL-23 signaling without affecting IL-12 activity. This approach has proven effective in treating autoimmune diseases such as psoriasis, colitis, and arthritis, where IL-23-mediated inflammation contributes significantly to disease pathology.

Other names
Interleukin-23 subunit alphaIL23A
02

Mechanism of action

Monoclonal antibodies bind specifically to the IL-23p19 subunit, preventing the formation of the IL-23 heterodimer and subsequent receptor binding, thereby blocking IL-23 signaling and downstream inflammatory responses.

03

Biological functions

Immune responseTh17 cell maintenance and expansionPro-inflammatory mediatorAngiogenesisActivation of JAK/STAT signaling pathwayInduction of effector cytokine secretion
04

Disease associations

Autoimmune diseasesPsoriasisColitisArthritisCancer progressionInflammation
05

Safety considerations

Increased risk of infections (due to immunosuppression)Potential for injection site reactionsLong-term effects on immune function are still being studiedPossible increased risk of malignancy (theoretical concern due to immune modulation)
06

Interacting drugs

Anti-IL-23p19 antibodies (e.g., guselkumab, risankizumab, tildrakizumab)
07

Biomarkers

IL-23p19 serum levelsIL-17A/F levelsIL-22 levelsRORγt expressionDisease activity scores (e.g., PASI for psoriasis, CDAI for Crohn's disease)

Beyond the preview

Go deeper on Interleukin-23 p19 Subunit (IL-23p19).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-23 p19 Subunit (IL-23p19).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call